Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults, comprising almost 40% of all lymphoid tumors. Although a subset of DLBCL patients can be cured with standard adriamycin-containing combination chemotherapy, the majority die of their disease. Robust clinical prognostic models such as the International Prognostic Index can be used to identify patients who are less likely to be cured with standard therapy 1 . However, such models do not provide specific insights regarding tumor cell biology, novel therapeutic targets or more effective treatment strategies. Furthermore, recent studies suggest that subsets of DLBCL may differ with respect to normal cell of origin and genetic bases for transformation as well as clinical outcome.
DLBCLs are thought to arise from normal antigen-exposed B-cells that have migrated to or through germinal centers (GC) in secondary lymphoid organs . These tumors also exhibit genetic changes that may be related to normal GC functions. For example, normal GC B-cells undergo vigorous clonal expansion and editing of the immunoglobulin receptor via processes that require DNA strand breaks. In small subsets of DLBCL, several translocations into the immunoglobulin locus have been described, including t(8;14), t (3;14) and t(14;18) 3 . A subset of DLBCLs also exhibits aberrant somatic hypermutation of genes that are not targeted by this editing process in normal GC B-cells 4 . However, a significant percentage of DLBCLs lack known genetic abnormalities.
Given the documented clinical and genetic heterogeneity of DLBCLs, it would be useful to have comprehensive molecular signatures of tumors that share similar features. In addition to highlighting potential pathogenetic mechanisms, such signatures might identify promising subtype-specific targets and pathways for therapeutic intervention.
With the advent of gene expression profiling, it is now possible to obtain signatures of DLBCL subtypes.
only.
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To date, transcriptional profiling of DLBCLs has been used to highlight similarities between subsets of tumors and normal B-cells and to identify features associated with unfavorable responses to empiric combination chemotherapy. For example, a series of molecular models have been described which relate DLBCL subsets to normal GC Bcells, in vitro activated peripheral blood B-cells or an unspecified, third group 5, 6 . In these studies, DLBCLs with features common to normal GC B-cells responded more favorably to standard empiric combination chemotherapy. In additional profiling studies, the molecular signatures of DLBCLs with different responses to standard chemotherapy were examined 7 . Two of the pathways associated with poor responses to current regimens have already been credentialed and targeted for possible therapeutic intervention ( 8 of a clinically similar disorder, classical Hodgkin lymphoma (nodular sclerosis subtype) 9, 10 . In the current study, we address the more difficult question of unrecognized biological heterogeneity within DLBCLs, using multiple clustering methods and comprehensive genetic analyses to identify discrete subsets of tumors.
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Materials and Methods

Case selection and Histologic classification
Tumor specimens and retrospective clinical data from 176 DLBCL patients were analyzed according to the Dana Farber/ Partners Cancer Care Institution Review Boardapproved protocol. All tumor specimens were nodal biopsies from newly diagnosed, 
Target cRNAs of oligonucleotide microarrays
Target cRNAs were prepared as previously described 7 . For 17 randomly selected tumors, 2 separate aliquots of RNA were used for target preparation and analysis.
Samples were hybridized to Affymetrix U133A and U133B oligonucleotide microarrays (Affymetrix, Santa Clara, CA) which include probe sets from ∼ 33,000 genes. Arrays were subsequently developed and scanned as previously described ( 
Gene expression analysis
A statistical analysis of the duplicate samples was used to identify genes with high reproducibility within duplicates and high variation across patient tumors (Supplementary Information). Genes were ranked using a robust F statistic and the top 5% (2118 genes) only.
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Unsupervised analysis by consensus clustering
Three unsupervised clustering algorithms were used in the analysis: hierarchical clustering (HC) 11 , self-organizing maps (SOM) 12 and model-based probabilistic clustering (PC) 13 (Supplementary Information). The stability of the identified clusters (i.e., sensitivity of the cluster boundaries to sampling variability) was assessed using consensus clustering 
Gene expression differential analysis
From the top 5% (2118-gene) pool, genes associated with each of the DLBCL clusters were identified using the binary distinction "cluster X vs. NOT cluster X". Genes were ranked according to the signal-to-noise ratio (SNR) (Supplementary Information).
Gene Set Enrichment Analyses (GSEA)
GSEA was performed as previously described 15 Enrichment was assessed by: 1) ranking the 2118 genes in the top 5% pool with respect to the phenotype "cluster 1 vs. not cluster 1"; 2) locating the represented members of a given gene set within the ranked 2118 genes; 3) measuring the proximity of the gene set to the overexpressed end of the ranked list with a Kolmogorov-Smirnoff (KS) score (with a higher score corresponding to a higher proximity); and 4) comparing the observed KS score to the distribution of 1000 permuted KS scores for all gene sets (Supplementary Information). A p < .005, corrected for multiple hypothesis testing (MHT-p), was used to identify highly significant associations between specific gene sets and DLBCL clusters.
Fluorescence in-situ hybridization (FISH)
Air-dried touch preparations were prepared from fresh frozen tumor specimens. 
Morphologic analysis of tumor infiltrating lymphocytes (TILS).
All study DLBCLs with available hematoxylin and eosin (H&E)-stained diagnostic specimens (119 tumors) were independently assessed for the presence of TILS by an expert morphologist (MM) who had no previous information regarding the DLBCL transcriptional profiles. For the majority of tumors, anti-CD2 stained specimens were also available for review. Tumors were initially scanned at high power (640X) to identify morphologically normal, CD2+ lymphocytes with round or oval nuclei and delicately dispersed chromatin; such lymphocytes were only scored when they directly infiltrated the tumor (TILS,
16
. Twenty-30 representative fields of the tumor were independently scored for TILS at 400X and an average TILS/400X score was obtained. DLBCLs were classified as having either less than or greater than 20 TILS/400X field. 
Immunohistochemistry (IHC)
Two
Cluster validation
An independent group of 221 newly diagnosed DLBCLs with available cDNA microarray ("lymphochip") profiles 5 
Cell-of-origin signature
DLBCLs from our dataset were sorted according to the most recent COO signature only.
Results
Identification of DLBCL consensus clusters
To identify biologically meaningful subsets of DLBCL with similar transcription profiles, we utilized a large series of tumors from highly representative, newly diagnosed patients (Supplementary Information). We were interested in DLBCL subsets that were sufficiently robust to be captured by multiple methods. For this reason, we used three different clustering algorithms (hierarchical clustering (HC), self-organizing maps (SOM), and probabilistic clustering (PC)) and the top 5% of genes with the highest reproducibility across duplicate samples and largest variation across patient tumors. In addition, we utilized a resampling-based method (consensus clustering) that automatically selects the most stable numbers of clusters with each algorithm.
With all 3 clustering algorithms, the most robust substructure included 3 discrete clusters (Fig. 1A, left panel ). There was a high level of agreement between clusters produced by the individual algorithms, with more than 84% of DLBCLs assigned to the same clusters by any two algorithms (Fig. 1A, right panel) . A meta-consensus confirmed that 141 of the 176 tumors were assigned to the same clusters by all 3 methods (Fig. 1B) . We predicted For personal use at PENN STATE UNIVERSITY on February 28, 2013. bloodjournal.hematologylibrary.org From 
Fig. 1 Identification of consensus clusters
A. Left panels). Consensus matrices produced by hierarchical clustering (HC, K=3), selforganizing maps (SOM, K=3) and probabilistic clustering (PC). Right panels). Comparisons of the cluster assignments of the different algorithms (PC vs. HC, HC vs. SOM and PC vs. SOM, respectively
Characterization of the DLBCL consensus clusters
Having defined the expression profiles of 3 discrete DLBCL clusters, the next challenge was to interpret them objectively. We first asked whether previously characterized, coregulated sets of genes were more abundant in specific clusters using GSEA ( The first DLBCL cluster was significantly enriched in genes involved in oxidative phosphorylation, mitochondrial function and the electron transport chain (Table 1A) .
More detailed analysis of this DLBCL cluster, termed "OxPhos", revealed increased expression of members of the NADH dehydrogenase complex and cytochrome c/cytochrome c oxidase (COX) complex as well as ATP synthase components and only.
For (Table 2A) The second DLBCL cluster was enriched in cell-cycle regulatory genes (Table 1A) , including CDK2 and MCM (minichromosome maintenance deficient) family members (Table 2B) 21 . These tumors also had increased expression of DNA repair genes including postmeiotic segregation increased 2 (PMS2) family members 22 , H2AX 23 , PTIP 24 and p53 (Table 2B ). This DLBCL cluster also had higher levels of many components of the BCR signaling cascade (CD19, Ig, CD79a, BLK, SYK, PLCγ2 and MAP4K) and additional B-cell specific or essential transcription factors (including PAX5, OBF-1, E2A, BCL6, STAT6 and MYC) (Table 2B ) 25, 26 . For this reason, this subset of DLBCLs was termed "BCR/Proliferation".
Unlike the other 2 DLBCL subsets, the third DLBCL cluster had a signature that was largely defined by the associated host response rather than the tumor itself (Table 1) . By GSEA, this cluster was enriched for markers of T-cell mediated immune responses and the classical complement pathway (Table 1A ). These tumors also had increased only.
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Detailed analysis of the third cluster, termed "Host Response (HR)", revealed increased expression of multiple components of the T-cell receptor (TCR) (TCRα and β and CD3 subunits), CD2, and additional molecules associated with T/NK-cell activation 27 and the complement cascade (Table 2C ). HR tumors also had more abundant monocyte/macrophage and dendritic cell transcripts, molecules required for efficient antigen processing and certain HLA class I antigens [28] [29] [30] [31] [32] [33] [34] [35] (Table 2C) . Consistent with the signature of an ongoing inflammatory/immune response, HR tumors had increased expression of interferon-induced genes, certain tumor necrosis family (TNF) ligands and receptors, cytokine receptors, adhesion molecules and extracellular matrix components [36] [37] [38] (Table 2C) .
Of note, patients in the 3 consensus clusters had similar 5-year survivals (OxPhos 53%, BCR/proliferation 60% and HR 54%, p = .53), suggesting that the clusters may be more useful for identifying potential pathogenetic mechanisms and cluster-specific rational therapeutic targets than predicting responses to empiric combination chemotherapy.
Genetic abnormalities and clinical features in the newly identified DLBCL clusters
Having identified 3 subclasses of DLBCL, we asked whether these subgroups differed with respect to known chromosomal translocations in the disease (t(14;18) and t(3; ), involving the BCL6 locus) ( Table 3 ). The distribution of t(14;18) and t(3; ) was examined in the 116 tumors with available data and no more than one translocation (one OxPhos tumor with both translocations was omitted from the analysis). There was an association between cluster membership and the examined genetic abnormalities (p = 0.059, Fisher exact test, Table 3 ). BCL2 translocations were more common in the Oxphos cluster whereas BCL6 translocations were more frequent in the BCR/proliferation cluster.
Translocations of either type were uncommon in the HR cluster (Table 3) .
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Immunohistochemical and morphological analysis of HR tumors
The unique characteristics of the HR cluster -fewer known genetic abnormalities and prominent host immune and inflammatory cell transcripts -prompted us to assess host immune cells in study tumors using morphologic and immunohistochemical approaches.
Hematoxylin-and-eosin and CD2-stained slides of study DLBCLs were evaluated for the presence of tumor infiltrating lymphocytes (TILs) by an expert morphologist who had no information regarding the DLBCL transcriptional profiles. HR tumors contained significantly higher numbers of TILS than DLBCLs in the other clusters (< 0. 
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Since HR tumors had more abundant CD2 and CD3ε transcripts (Table 2C) , perforin 1 and the CD28 co-stimulatory molecule 44 -suggest that these tumors include a mixed population of activated T/NK-cells (Table 2C) .
For
Fig. 2 T-and dendritic cell infiltrates in study DLBCLs.
A) Numbers of normal infiltrating CD2+ and CD3+ cells and GILT-positive dendritic cells in primary DLBCLs in each cluster. HR tumors included significantly higher numbers of CD2+ and CD3+ T-cells than DLBCLs in the other clusters (p = .005 and .003, respectively, Kruskal-Wallis exact test). HR tumors also contained higher numbers of GILT+ dendritic cells (p = .06, KruskalWallis exact test).
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Fig. 2 T-and dendritic cell infiltrates in study DLBCLs (continued).
B) Hematoxylin-and-eosin staining and CD3 and GILT immunostaining of a representative HR tumor.
In addition to having higher numbers of infiltrating T and NK cells, HR tumors had increased levels of likely macrophage and dendritic cell transcripts, including the gamma interferon-induced lysosomal thiol reductase, GILT 17, 34 (Table 2C ). Since GILT is required for effective peptide processing and optimal antigen presentation 34,45,46 , we used GILT immunostaining to both identify and characterize the dendritic cells in study tumors. When compared to the other clusters, HR tumors contained increased numbers of GILT+ dendritic cells (p = .06, Kruskal-Wallis test, Figs. 2A and B) .
For this reason, we further characterized tumor dendritic cells (DC) with S100, CD1a and CD123. These markers distinguish interdigitating DC (S100+ CD1a -CDC123-) that interact with antigen-specific T-cells in secondary lymphoid organs from other DC subtypes 47, 48 . There was no detectable CD1a expression in study DLBCLs and only 2 tumors (non-HR) contained CD123 positive cells. In marked contrast, S100+ DC were readily detectable and significantly more abundant in HR tumors than DLBCLs from other clusters (p = .009, Krushal Wallis test). In addition, the numbers of CD2+/CD3+
infiltrating T-cells and GILT+/S100+ DC were highly correlated in individual tumors (p < 0001, Jonckheere-Terpstra test) ( For personal use at PENN STATE UNIVERSITY on February 28, 2013. bloodjournal.hematologylibrary.org From contact and T-cell surface molecules, such as SEMA4D/CD100 and LAG3/CD223, that promote DC maturation and activation (Table 2C) 44,49-51 .
Validation of DLBCL consensus clusters in an independent dataset
After defining 3 consensus clusters in our own DLBCL series, we asked whether there were similar clusters in an independent group of newly diagnosed DLBCLs with available gene expression profiles 5 . Using the overlapping set of highly reproducible/highly variable genes (703 common genes), our clustering procedure subdivided the independent DLBCL series into 2, rather than 3, major groups (Fig.3 , right panel and Supplemental Information). The signature for one of the independent clusters was highly enriched for HR transcripts (overlap P-value <2.2 X 10 -16 ) (Fig. 3A , top left panel). We further analyzed the "non-HR" tumors by clustering this group in the space of non-HR markers. "Non-HR" tumors separated into 2 discrete clusters with highly significant enrichment for either BCR/proliferation or OxPhos transcripts (overlap P-value < 0.0009) (Fig. 3B, bottom panels) .
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Relationship of consensus clusters to the cell-of-origin signature
Recent studies suggest that subsets of DLBCL share elements of the transcriptional profile of normal purified germinal center B-cells (GCB) or in vitro-activated peripheral blood B-cells (ABC) while other DLBCLs lack these features (Other) 5, 6 . To compare the newly defined consensus clusters (CC) with these cell-of-origin (COO) subsets, we first classified our tumors with respect to COO ( 6 , Methods and Supplementary Information).
Of note, tumors identified as GCB were associated with significantly longer overall survivals (p = .003).
Comparison of the CC and COO assignments indicates that the two classification schema are capturing largely different aspects of DLBCL biology (Fig.4 and Supplementary Information). Although 53% of tumors in the BCR/proliferation cluster and 46% of tumors in the OxPhos cluster were classified as GC-like, the remainder were designated ABC or Other (Fig. 4) . In the HR cluster, there were relatively more unspecified (Other) DLBCLs (Fig.4) In DLBCLs, additional sets of co-regulated genes (Proliferation, MHC class II and Lymph Node) were previously reported to be expressed independently of the COO signature 5 .
For these reasons, we asked whether these additional co-regulated gene sets contributed to consensus cluster signatures using GSEA. Not surprisingly, the BCR/proliferation signature had some evidence of enrichment with the previously described proliferation genes 5 (MHT p = 0.06, Table 1B ). There was also highly significant enrichment of the LN gene set in our HR signature (p = < 0.001, Table 1B ). For these reasons, it will be important to identify HR tumors with pre-existing abundant T-and dendritic-cell infiltrates and further characterize their associated underlying immune response. Such directed approaches to HR tumors and the other newly identified DLBCL consensus clusters will likely define more rational treatment targets in this heterogeneous disease.
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